Deuterium Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Deuterium Capital Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,572	Closed	-$514K	–	58
2024 Q2	$514K	Hold	12,572	–	–	0.87%	18
2024 Q1	$531K	Buy	+12,572	New	+$528K	0.95%	19

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Deuterium Capital Management's CERE Position: Q3 2024 in Review

Deuterium Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 12,572 shares — an estimated $514K sold.

Deuterium Capital Management first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $531K in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Deuterium Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Deuterium Capital Management sold 12,572 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $514K.
Deuterium Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
Deuterium Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $531K in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Deuterium Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.